Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

P Stock Price - Pandora Media Inc. Stock Quote (U.S.: NYSE) - MarketWatch

15h marketwatch
Pandora Media Inc. shares rose more than 2% late Wednesday after the streaming company announced a plan to save about $45 million and said it wants to expand in Atlanta. The "organizational restructuring" will focus on ad tech and audience development while also simplifying the organization "into a flatter structure for smarter, faster execution," Pandora said in a statement. Eliminating roles and other cost-saving measures will be immediate and are expected to result in combined annualized savings of about $45 million to the company's adjusted EBITDA, Pandora said. (435-0)

BRIEF-Celgene Receives Antitrust Clearance For Juno Acquisition

23h reuters
* CELGENE CORP - ‍CELGENE EXPECTS JUNO TRANSACTION TO CLOSE IN Q1 OF 2018​ Source text for Eikon: Further company coverage: (56-0)

What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?

2018-02-20 zacks
Juno Therapeutics Inc. (JUNO - Free Report) is expected to report fourth-quarter 2017 results on Mar 7, after the market closes. Last quarter, the company delivered a positive earnings surprise of 10.98%. (106-0)

Pharmaceutical Titan’s Senate Bid Will Test Voters’ Views on Drug Prices - Bloomberg

2018-02-20 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (62-0)

Celgene Reports Positive Data on Dermatology Drug Otezla

2018-02-19 zacks
Celgene Corporation (CELG - Free Report) announced data from phase III trial, RELIEF, on dermatology drug Otezla in a late-breaking oral presentation at the 2018 American Academy of Dermatology ("AAD") Annual Meeting. (128-0)

Merger And Acquisition: What Can Investors Learn From The Seattle Genetics Buyout Of Cascadian?

2018-02-18 seekingalpha
This M&A satisfied 50% of our criteria conducive to a buyout. For one, there is pipeline synergy. (107-1)

At $96.14, Celgene (CELG) a Sell

2018-02-16 investorplace
Celgene (CELG) remains a Sell this week based on the most current comparative pricing of its shares and stock market rankings. Celgene Corp's (NASDAQ:CELG) Sell recommendation is significant considering it is in an industry group and sector that are ranked near average in attractiveness. Influencing this recommendation are analytical scoring that is below average, a ranking in the company's sector group that is in the bottom quarter, a ranking in its industry group that is in the bottom quarter, and a numerical calculation of risk/reward that is unattractive. (56-0)

BioXcel Therapeutics Seeks $69 Million U.S. IPO

2018-02-16 seekingalpha
The firm is using the advanced data and AI technologies of its parent company to improve its drug development efforts. (381-3)

Molson Coors Brewing Co Stock Is Setting Up and Could Explode Higher

2018-02-16 investorplace
Unlike most stocks, the past 12 months have not been too kind to Molson Coors Brewing Co (NYSE:TAP). However, after reporting third quarter earnings, TAP stock finally has some pep in its step. Shares jumped 6.3% on Wednesday, closing at $80.45. This pop comes just days after shares made new 52-week lows. (317-0)

No, Really, Save That Placenta - Bloomberg

2018-02-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (231-0)

Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y

2018-02-15 zacks
Agios Pharmaceuticals, Inc. (AGIO - Free Report) posted fourth-quarter 2017 loss of $1.81 per share, wider than both the Zacks Consensus Estimate of a loss of $1.65 and the year-ago loss of $1.34. (100-0)

BRIEF-Celgene Says Otezla Phase II Data Showed Clinically Meaningful Improvements In Active Ulcerative Colitis Patients

2018-02-15 reuters
* OTEZLA® (APREMILAST) PHASE II DATA SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS (56-0)

Nektar Therapeutics-Bristol-Myers Squibb Deal: A Buyout Must Wait - Bloomberg

2018-02-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (129-0)

Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides

2018-02-14 247wallst
While the market has bounced back smartly over the past few sessions, one thing is for sure: the baby was tossed out with the proverbial bathwater in many sectors. Nowhere is that more true than with large cap biotech stocks. With indiscriminate selling absolutely punishing some of the top companies, one analyst says now is the time to buy. (130-2)

Top Analyst Upgrades and Downgrades: ADT, CBOE, Celgene, JPMorgan, 3M, NetApp, Total, Tyson Foods, Weatherford and More

2018-02-13 247wallst
Monday’s markets closed sharply higher after a recovery rally was seen on Friday, but Tuesday’s opening bell was indicated to be weak for stocks. The bull market is just a month shy of being nine years old, and the one trend that has served investors huge rewards for over five years now has been to buy the pullbacks. Investors also are reconsidering how to position their portfolios for 2018, as higher wages, interest rates and even inflation concerns are being countered by tax reform, accelerated corporate earnings and stronger GDP growth. (120-2)


CUSIP: 151020112